Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | June 22, 2022 | June 24, 2022 |
| EyePoint, Inc.EYPT · Entity 5702 | Director · President and CEO | July 10, 2026 | July 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date June 22, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2022-06-22 transaction · row 1
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 40,000 · Balance 40,000 F1: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2032-06-22 | Direct | 65,000 |
Reported balance
After 2022-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-22 · Grant · Acquired 65,000 · Balance 65,000 F2: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock.
F2: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.
EyePoint, Inc.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,594 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Exercise / conversion · Acquired 16,667 · Balance 17,653 Row 2 · 2026-07-10 · Tax withholding · Disposed 8,059 · Balance 9,594 F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Exercise / conversion · Disposed 16,667 · Balance 0 F3: The restricted stock units vested in three ratable annual installments beginning July 10, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 177,431 |
Reported balance
Holding disclosure · report date 2026-07-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 177,431 F2: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3: The restricted stock units vested in three ratable annual installments beginning July 10, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2024 Filed Jan 10, 2024 02:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 20,793 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · derivative · entry 5 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,587 Underlying: Common Stock · 20,793 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 6,528 | $20.40 | $133,171.20 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,486 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 20,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · derivative · entry 4 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-01-04 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 90,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · derivative · entry 3 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-01-05 F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 22:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-23-005881 · primarydocument.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-07-10 F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 22:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005881 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning July 10, 2024. F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning July 10, 2024. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 13:13 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 62,380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005440 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,380 Underlying: Common Stock · 62,380 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024. F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 4,967 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001333 · primarydocument.xml · derivative · entry 6 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,967 Underlying: Common Stock · 4,967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning February 9, 2022. F3 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 7,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001333 · primarydocument.xml · derivative · entry 5 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 7,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three annual installments beginning February 9, 2023. F2 · derivative.expiration_date: The restricted stock units vests in three annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 1,722 | $4.17 | $7,180.74 |
DisclosureSEC source: 0001562180-23-001333 · primarydocument.xml · nonDerivative · entry 4 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,221 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 2,426 | $4.17 | $10,116.42 |
DisclosureSEC source: 0001562180-23-001333 · primarydocument.xml · nonDerivative · entry 3 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,943 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001333 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001333 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 22:56 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 124,755 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-23-000346 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,755 Underlying: Common Stock · 124,755 shares Expires 2033-01-05 F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 12:38 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 15,258 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007459 · primarydocument.xml · derivative · entry 3 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date. F2 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 12:38 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 4,479 | $5.42 | $24,276.18 |
DisclosureSEC source: 0001562180-22-007459 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,402 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 12:38 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 15,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007459 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 65,300 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001562180-22-006581 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,300 Underlying: Common Stock · 65,300 shares Expires 2032-09-06 F1 · derivative.exercise_date: The option to purchase will vest and become exercisable over a three year period as follows: 50% at the one year anniversary of grant and then ratably over the remaining twenty-four months Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 18:37 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001485003-22-000085 · wf-form4_165611022606239.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 18:37 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001485003-22-000085 · wf-form4_165611022606239.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-22-001414 · primarydocument.xml · derivative · entry 4 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2032-02-09 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 4,966 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001414 · primarydocument.xml · derivative · entry 3 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,934 Underlying: Common Stock · 4,966 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022. F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 21,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001414 · primarydocument.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 4,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001414 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:50 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 305,000 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001562180-21-006808 · primarydocument.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 305,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:50 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 15,258 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-006808 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,258 Underlying: Common Stock · 15,258 shares Expires 2031-11-01 Read SEC document |
| November 01, 2021 Filed Sep 9, 2022 20:09 UTC Amendment | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 239,700 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001562180-22-006580 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,700 Underlying: Common Stock · 239,700 shares Expires 2031-11-01 F1 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. F2 · balance_after: Due to an administrative error, the Reporting Person's previous Form 4 filed on November 3, 2021 incorrectly reported the Reporting Person receiving an option grant of 305,000 shares of common stock when it should have been reported as 239,700 shares of common stock. Read SEC document |
| May 03, 2021 Filed May 5, 2021 18:18 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 92,500 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001485003-21-000094 · wf-form4_162025307065556.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2031-05-03 F1 · derivative.exercise_date: The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis. Read SEC document |
| May 06, 2020 Filed May 8, 2020 17:44 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 59,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001485003-20-000052 · wf-form4_158897424079293.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option was granted on May 6, 2020 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002047 · primarydocument.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002047 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:52 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003667 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-21 Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 20:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionDeferred Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003626 · primarydocument.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 20:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003626 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:16 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 52,500 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001485003-19-000043 · wf-form4_156114817714929.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| April 12, 2019 Filed Apr 16, 2019 12:16 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001562180-19-002284 · primarydocument.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2019 Filed Apr 16, 2019 12:16 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 20,000 | $1.77 | $35,400.00 |
DisclosureSEC source: 0001562180-19-002284 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 12:25 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 5,000 | $1.89 | $9,450.00 |
DisclosureSEC source: 0001562180-19-002168 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:02 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionDeferred Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018714 · doc4.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:02 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018714 · doc4.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document |
| June 21, 2018 Filed Jun 26, 2018 18:13 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantDeferred Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018098 · doc4.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| June 21, 2018 Filed Jun 26, 2018 18:13 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 26,667 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000899243-18-018098 · doc4.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 26,667 shares Expires 2028-06-21 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:26 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 52,500 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001485003-18-000094 · wf-form4_152900796376335.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2018 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:05 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantDeferred Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029147 · doc4.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:05 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000899243-17-029147 · doc4.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:46 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantStock Option · Derivative | 8,072 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001485003-17-000068 · wf-form4_149557234750328.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,072 Underlying: Common Stock · 8,072 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option was granted on May 19, 2017 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 17:58 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0000899243-16-035512 · doc4.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2026-09-26 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on September 26, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.